Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial

201761 citationsJournal Articlegold Open Access

Authors

Christopher LaGanke · School of the Art Institute of Chicago

Lawrence Samkoff · School of the Art Institute of Chicago

Keith R. Edwards · School of the Art Institute of Chicago

Lily Jung Henson · School of the Art Institute of Chicago

Pavle Repovic · School of the Art Institute of Chicago

Sharon Lynch · School of the Art Institute of Chicago

Lael A. Stone

Abstract

This study provides Class III evidence that anti-semaphorin 4D antibody VX15/2503 at various doses was safe and well tolerated vs placebo, although an increase in treatment-emergent adverse events in the treatment group could not be excluded (risk difference -0.7%, 95% CI -28.0% to 32.7%).

Topics & Keywords

Axon Guidance and Neuronal Signaling Toxin Mechanisms and Immunotoxins Hereditary Neurological Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology Neuroimmunology & Neuroinflammation

Volume 4, Issue 4, pp. e367-e367

DOI: 10.1212/nxi.0000000000000367

Field-Weighted Citation Impact: 2.63